Coloplast appoints new President of its global Interventional Urology business
Effective January 2, 2023,Tommy Johnswill enter a new role as President & Senior Vice President of Coloplast’s global Interventional Urology (IU) business, replacing Steve Blum, who has decided to retire at the end of 2022.
"Tommy has been with the company since 2015 and is the right person to lead our IU business going forward. He currently leads the IU Global Marketing & Innovation function, and as part of the global leadership team, he has helped bring the organization to where it is today. Tommy is a great ambassador for Coloplast and our company values and through his collaborative spirit he has built strong relationships not just in IU but across the Coloplast Group.” says Kristian Villumsen, Coloplast’s CEO.
Tommy Johns brings 30 years of experience in the medical device industry through his careers with Medtronic, Smiths Medical and Coloplast. He began his career with Coloplast in 2015 as Vice President and General Manager, Urology Care, North America, and was promoted the following year to Vice President of Global Marketing and Innovation, Interventional Urology.
"I am passionate about the work we do in Interventional Urology and I am excited to step into a new role. I look forward to leading our IU business into the future where we will bring existing and new products and solutions to more and more customers around the world. We are a purpose-driven growth business – and a great place to work," says Tommy Johns.
Tommy Johns replaces Steve Blum who has decided to retire after several successful decades in the global healthcare industry, including six years with Coloplast.
“Steve is a great leader with an impressive track record. He has successfully led the IU team through the pandemic, while simultaneously preparing the business for growth. Currently, we are seeing solid growth rates across IU and combined with the investments we have been making into innovation, the business is in a very good place. I want to thank Steve for his contributions to the company and wish him a happy retirement,” says Kristian Villumsen.
Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare. Our business includes Ostomy Care, Continence Care, Wound and Skin Care, Interventional Urology and Voice & Respiratory Care. We operate globally and employ more than 14,000 employees.
Global Press Contact
Peter Mønster, Senior Media Relations Manager
+45 4911 2623
U.S. Press Contact
Kate Merwin, Head of Communications
AttachmentsTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Camposol Holding PLC - Invitation to the Third Quarter 2022 Financial Results Presentation26.11.2022 00:03:54 CET | Press release
Camposol Holding PLC will announce its financial results of the third quarter of 2022 on Tuesday, November 29, at 13:00 (GMT -5). The call will be conducted by our CEO, Jose Antonio Gomez - Bazan. Use the following link to register and participate in the call: Participant Registration URL: https://register.vevent.com/register/BI64a53cb1ca2843bdb219d095254b1c94 Participants are advised to log on to the service and check their settings a few minutes before the conference call begins. About CAMPOSOL CAMPOSOL is a multinational company that provides families around the world with fresh and healthy food. We have operations in Chile, Colombia, Mexico, Peru, and Uruguay, commercial offices in North America, Europe, and Asia, a corporate office in Costa Rica, and trusted relationships with the main supermarkets worldwide, as well as customers in more than 40 countries. We are involved in the harvest, processing, and marketing of high-quality agricultural products such as avocados, blueberries,
Cool Company Ltd. - Granting of Share Options and Restricted Stock Units to Primary Insiders and Mandatory Notifications of Trade25.11.2022 22:42:08 CET | Press release
Bermuda, November 25, 2022: Reference is made to the stock exchange notice from Cool Company Ltd. (“CoolCo” or the “Company”) on November 25, 2022 announcing that the board of directors of the Company (the “Board”) had resolved to implement a long-term incentive program for employees, management and board members of the Company and its affiliates (the "LTIP"). Pursuant to the LTIP, the Board has resolved to grant options over a total number of 1,237,423 shares and 115,000 restricted stock units to employees, management and board members of the Company (equivalent to approximately 2.25% and 0.2% of the Company's share capital, respectively), of which 11,507 restricted stock units and options over a total number of 742,454 shares were granted to primary insiders of the Company (equivalent to approximately 0.02% and 1.38% of the Company's share capital, respectively). Each share option, when exercised, carries the right to acquire one share in CoolCo, giving the right to acquire up to in
Cool Company Ltd. - Approval of Long-Term Incentive Plan25.11.2022 20:13:34 CET | Press release
Bermuda, November 25, 2022: The board of directors (the “Board”) of Cool Company Ltd. (“CoolCo” or the “Company”) has resolved to implement a long-term incentive plan (the “LTIP”) for employees, management and board members of the Company and its affiliates. The overall purpose of the LTIP is to promote the success of the Company for the benefit of its shareholders, by providing a framework for the retention and incentivization of employees using the Company’s equity and thereby aligning their interests with the Company and its affiliates. The LTIP provides for the grant of equity awards, with the intention being for the initial awards to be granted as options (“Options”) and restricted stock units (the “RSUs”), as further detailed below. Shares used under the LTIP are expected to be covered by the Board's authorization to issue authorized and unissued shares in connection with a grant of warrants, options or other securities with rights to convert such securities into shares of the Co
Fingerprint Cards AB (publ) publishes the final outcome of the rights issue25.11.2022 20:10:00 CET | Press release
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS), AUSTRALIA, JAPAN, CANADA, HONG KONG, NEW ZEALAND, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE IN ACCORDANCE WITH APPLICABLE LAW. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE SECTION "IMPORTANT INFORMATION" AT THE END OF THE PRESS RELEASE. The final outcome in Fingerprint Cards AB’s (publ) (“Fingerprints” or the “Company”) SEK 300 million rights issue of B-units (“B-units”), consisting of new B-shares and warrants (the “Fully Guaranteed Rights Issue”) shows that 16,851,001 B-units, corresponding to approximately 84.9 per cent of the B-units offered, have been subscribed for with support of unit subscription rights. The remaining 2,987,938 B-units have been subscribed for without support of unit subscription rights, corres
Fingerprint Cards AB (publ) offentliggör slutligt utfall i företrädesemissionen25.11.2022 20:10:00 CET | Pressemelding
EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, DIREKT ELLER INDIREKT, INOM ELLER TILL USA (INKLUSIVE DESS TERRIRTORIER OCH BESITTNINGAR), AUSTRALIEN, JAPAN, KANADA, HONGKONG, NYA ZEELAND, SINGAPORE ELLER SYDAFRIKA ELLER NÅGON ANNAN JURISDIKTION DÄR DISTRIBUTION ELLER OFFENTLIGGÖRANDE SKULLE VARA OLAGLIGT ELLER KRÄVA REGISTERING ELLER ANDRA ÅTGÄRDER ENLIGT GÄLLANDE LAG. ANDRA RESTRIKTIONER ÄR TILLÄMPLIGA. VÄNLIGEN SE AVSNITTET "VIKTIG INFORMATION" I SLUTET AV DETTA PRESSMEDDELANDE. Det slutliga utfallet i Fingerprint Cards AB:s (publ) (“Fingerprints” eller “Bolaget”) företrädesemission av B-units om 300 miljoner kronor (”B-units”), bestående av nya B-aktier och teckningsoptioner (den ”Fullt Garanterade Företrädesemissionen”) visar att 16 851 001 B-units, motsvarande cirka 84,9 procent av erbjudna B-units, har tecknats med stöd av uniträtter. Återstående 2 987 938 B-units tecknades utan stöd av uniträtter, motsvarande cirka 15,1 procent av erbjudna B-units. Tillsammans utgör te